Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 10/2008

Open Access 01-10-2008 | Article

Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa

Authors: R. E. Barth, J. T. M. van der Meer, A. I. M. Hoepelman, P. A. Schrooders, D. A. van de Vijver, S. P. M. Geelen, H. A. Tempelman

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 10/2008

Login to get access

Abstract

The purpose of this study was to assess the one-year efficacy of highly active antiretroviral therapy (HAART) administered by general practitioners in a primary care community clinic in rural South Africa. We performed an observational cohort study of 675 treatment-naïve human immunodeficiency virus (HIV)-infected patients (including 66 children) who began HAART at least 12 months prior to the data analyses. Throughout treatment, the CD4+ T-cell count (percentage of CD4+ T-cells in children) and plasma HIV-RNA level were determined and the patient’s weight was recorded. The primary outcome was mortality. Secondary outcomes were viral suppression, immunological response, and weight gain. One year after the start of HAART, 100 of the 675 (15%) patients were lost to follow-up and 119 patients (18%), including six children, died. Mortality was highest during the first few months of treatment. Based on an on-treatment analysis at one year after the start of therapy, 83% of adults and 71% of children had a viral load <400 copies/ml; the viral load was <50 copies/ml in 70% of adults and 61% of children. At one year, the mean CD4+ T-cell count in adults had increased by 236/mm3, and the mean body mass index (BMI) had increased by 3.5 kg/m2. In children, the mean CD4% had increased by 17.6. A low Karnofsky score and a low baseline CD4+ T-cell count were independently associated with death. In addition to these factors, a low baseline BMI and gender were predictive of a poor immunological outcome. Our study shows that adequately monitored HIV/acquired immunodeficiency syndrome (AIDS) care administered by general practitioners and their staff is feasible and leads to good results in a rural, primary care center in sub-Saharan Africa. In order to achieve even better results, early mortality should be reduced and efforts should be made to start HAART earlier.
Literature
4.
go back to reference Egger M, May M, Chêne G, Philips AN, Ledergerber B, Dabis F, Costagliola D, D’Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360:119–129PubMedCrossRef Egger M, May M, Chêne G, Philips AN, Ledergerber B, Dabis F, Costagliola D, D’Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360:119–129PubMedCrossRef
5.
go back to reference Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F (2001) Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 15:1369–1377PubMedCrossRef Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F (2001) Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 15:1369–1377PubMedCrossRef
6.
go back to reference Laurent C, Diakhaté N, Gueye NFN, Touré MA, Sow PS, Faye MA, Gueye M, Lanièce I, Touré Kane C, Liégeois F, Vergne L, Mboup S, Badiane S, Ndoye I, Delaporte E (2002) The Senegalese government’s highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 16:1363–1370PubMedCrossRef Laurent C, Diakhaté N, Gueye NFN, Touré MA, Sow PS, Faye MA, Gueye M, Lanièce I, Touré Kane C, Liégeois F, Vergne L, Mboup S, Badiane S, Ndoye I, Delaporte E (2002) The Senegalese government’s highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 16:1363–1370PubMedCrossRef
7.
go back to reference Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N, Goemaere E (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18:887–895PubMedCrossRef Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N, Goemaere E (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18:887–895PubMedCrossRef
8.
go back to reference Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, Yiannoutsos CT, Musick B, Einterz R, Fife KH, Tierney WM (2006) Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 20:41–48PubMedCrossRef Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, Yiannoutsos CT, Musick B, Einterz R, Fife KH, Tierney WM (2006) Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 20:41–48PubMedCrossRef
9.
go back to reference Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, George E, Kenel-Pierre S, Wright PF, Gulick R, Johnson WD Jr, Pape JW, Fitzgerald DW (2005) Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353:2325–2334PubMedCrossRef Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, George E, Kenel-Pierre S, Wright PF, Gulick R, Johnson WD Jr, Pape JW, Fitzgerald DW (2005) Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353:2325–2334PubMedCrossRef
10.
go back to reference Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, Carrieri MP, Spire B, Ford N, Tassie JM, Guerin PJ, Brasher C (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367:1335–1342PubMedCrossRef Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, Carrieri MP, Spire B, Ford N, Tassie JM, Guerin PJ, Brasher C (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367:1335–1342PubMedCrossRef
11.
go back to reference DART Virology Group and Trial Team (2006) Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 20:1391–1399CrossRef DART Virology Group and Trial Team (2006) Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 20:1391–1399CrossRef
13.
go back to reference Hosegood V, Vanneste AM, Timaeus IM (2004) Levels and causes of adult mortality in rural South Africa: the impact of AIDS. AIDS 18:663–671PubMedCrossRef Hosegood V, Vanneste AM, Timaeus IM (2004) Levels and causes of adult mortality in rural South Africa: the impact of AIDS. AIDS 18:663–671PubMedCrossRef
17.
go back to reference Ivers LC, Kendrick D, Doucette K (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41:217–224PubMedCrossRef Ivers LC, Kendrick D, Doucette K (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41:217–224PubMedCrossRef
18.
go back to reference Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team (2006) Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 296:769–781PubMedCrossRef Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team (2006) Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 296:769–781PubMedCrossRef
19.
go back to reference Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354:251–260PubMedCrossRef Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354:251–260PubMedCrossRef
20.
go back to reference ART-LINC Collaboration and ART-CC groups (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367:817–824CrossRef ART-LINC Collaboration and ART-CC groups (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367:817–824CrossRef
21.
go back to reference van der Sande MA, Schim van Der Loeff MF, Aveika AA, Sabally S, Togun T, Sarge-Njie R, Alabi AS, Jaye A, Corrah T, Whittle HC (2004) Body mass index at time of HIV diagnosis: a strong and independent predictor of survival. J Acquir Immune Defic Syndr 37:1288–1294PubMedCrossRef van der Sande MA, Schim van Der Loeff MF, Aveika AA, Sabally S, Togun T, Sarge-Njie R, Alabi AS, Jaye A, Corrah T, Whittle HC (2004) Body mass index at time of HIV diagnosis: a strong and independent predictor of survival. J Acquir Immune Defic Syndr 37:1288–1294PubMedCrossRef
22.
go back to reference Van Damme W, Kober K, Laga M (2006) The real challenges for scaling up ART in sub-Saharan Africa. AIDS 20:653–656PubMedCrossRef Van Damme W, Kober K, Laga M (2006) The real challenges for scaling up ART in sub-Saharan Africa. AIDS 20:653–656PubMedCrossRef
23.
go back to reference Nattrass N (2006) South Africa’s “rollout” of highly active antiretroviral therapy: a critical assessment. J Acquir Immune Defic Syndr 43:618–623PubMed Nattrass N (2006) South Africa’s “rollout” of highly active antiretroviral therapy: a critical assessment. J Acquir Immune Defic Syndr 43:618–623PubMed
25.
go back to reference O’Brien DP, Sauvageot D, Zachariah R, Humblet P; Medecins Sans Frontieres (2006) In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 20:1955–1960PubMedCrossRef O’Brien DP, Sauvageot D, Zachariah R, Humblet P; Medecins Sans Frontieres (2006) In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 20:1955–1960PubMedCrossRef
26.
go back to reference Chan KC, Yip B, Hogg RS, Montaner JS, O’Shaughnessy MV (2002) Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States. AIDS 16:1693–1695PubMedCrossRef Chan KC, Yip B, Hogg RS, Montaner JS, O’Shaughnessy MV (2002) Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States. AIDS 16:1693–1695PubMedCrossRef
27.
go back to reference Erikstrup C, Kallestrup P, Zinyama R, Gomo E, Mudenge B, Gerstoft J, Ullum H (2007) Predictors of mortality in a cohort of HIV-1-infected adults in rural Africa. J Acquir Immune Defic Syndr 44(4):478–483PubMedCrossRef Erikstrup C, Kallestrup P, Zinyama R, Gomo E, Mudenge B, Gerstoft J, Ullum H (2007) Predictors of mortality in a cohort of HIV-1-infected adults in rural Africa. J Acquir Immune Defic Syndr 44(4):478–483PubMedCrossRef
28.
go back to reference Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R (2006) When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther 11:63–72PubMed Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R (2006) When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther 11:63–72PubMed
29.
go back to reference Koenig SP, Kuritzkes DR, Hirsch MS, Léandre F, Mukherjee JS, Farmer PE, del Rio C (2006) Monitoring HIV treatment in developing countries. BMJ 332:602–604PubMedCrossRef Koenig SP, Kuritzkes DR, Hirsch MS, Léandre F, Mukherjee JS, Farmer PE, del Rio C (2006) Monitoring HIV treatment in developing countries. BMJ 332:602–604PubMedCrossRef
30.
go back to reference Colebunders R, Moses KR, Laurence J, Shihab HM, Semitala F, Lutwama F, Bakeera-Kitaka S, Lynen L, Spacek L, Reynolds SJ, Quinn TC, Viner B, Mayanja-Kizza H (2006) A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis 6:53–59PubMedCrossRef Colebunders R, Moses KR, Laurence J, Shihab HM, Semitala F, Lutwama F, Bakeera-Kitaka S, Lynen L, Spacek L, Reynolds SJ, Quinn TC, Viner B, Mayanja-Kizza H (2006) A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis 6:53–59PubMedCrossRef
31.
go back to reference Basenero A, Castelnuovo B, Birabwa E, John L, MacAdam K, Schlech W, Kambugu A (2007) Inadequacy of clinical and immunological criteria in identifying virologic failure of 1st line ART: the Ugandan experience. In: Program and abstracts of the 4th International Aids Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia July, 2007, abstract WEAB102 Basenero A, Castelnuovo B, Birabwa E, John L, MacAdam K, Schlech W, Kambugu A (2007) Inadequacy of clinical and immunological criteria in identifying virologic failure of 1st line ART: the Ugandan experience. In: Program and abstracts of the 4th International Aids Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia July, 2007, abstract WEAB102
32.
go back to reference Hosseinipour M, van Oosterhout J, Weigel R, Mzigangira D, Saukila N, Mhango B, Phiri R, Phiri S, Kumwenda J (2007) Validating clinical and immunological definitions of antiretroviral treatment failure in Malawi. In: Program and abstracts of the 4th International Aids Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 2007, abstract WEAB101 Hosseinipour M, van Oosterhout J, Weigel R, Mzigangira D, Saukila N, Mhango B, Phiri R, Phiri S, Kumwenda J (2007) Validating clinical and immunological definitions of antiretroviral treatment failure in Malawi. In: Program and abstracts of the 4th International Aids Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 2007, abstract WEAB101
33.
go back to reference Mannheimer S, Friedland G, Matts J, Child C, Chesney M (2002) The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 34:1115–1121PubMedCrossRef Mannheimer S, Friedland G, Matts J, Child C, Chesney M (2002) The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 34:1115–1121PubMedCrossRef
35.
go back to reference Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, Rachlis B, Wu P, Cooper C, Thabane L, Wilson K, Guyatt GH, Bangsberg DR (2006) Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296:679–690PubMedCrossRef Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, Rachlis B, Wu P, Cooper C, Thabane L, Wilson K, Guyatt GH, Bangsberg DR (2006) Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296:679–690PubMedCrossRef
Metadata
Title
Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa
Authors
R. E. Barth
J. T. M. van der Meer
A. I. M. Hoepelman
P. A. Schrooders
D. A. van de Vijver
S. P. M. Geelen
H. A. Tempelman
Publication date
01-10-2008
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 10/2008
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-008-0534-2

Other articles of this Issue 10/2008

European Journal of Clinical Microbiology & Infectious Diseases 10/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.